Navigation Links
PharmAthene Reports First Quarter 2011 Financial and Operating Results
Date:5/11/2011

to our Phase II rPA anthrax vaccine program.  During the quarter we submitted 36 month stability data on our SparVax® vaccine to the Biomedical Advanced Research and Development Authority (BARDA).  These data, combined with our finalization of the technology transfer process to Diosynth in RTP, North Carolina, are pivotal milestones in regards to potential future advanced development funding for the program."

Mr. Richman continued, "In addition, we achieved a significant clinical milestone by completing dosing in a Phase I dose escalation clinical trial of Valortim®.  The trial enrolled 28 healthy volunteers who received escalating IV doses of 1, 5, or 10 mg/kg of Valortim® (or placebo).  We anticipate the in-life portion of the trial will be completed in the third quarter of 2011 with final results available later in the year."

"Finally, regarding our on-going litigation against SIGA Technologies, Inc., all post-trial briefs were filed and closing arguments were held prior to the end of April 2011.  I am pleased with how our legal team presented our case and that the evidence is in and the case is before the Vice Chancellor.  PharmAthene looks forward to the Court's decision."

Update on Quarterly Conference Calls:PharmAthene will continue to issue quarterly press releases of its financial and operating results.  However, management has decided to discontinue conducting regular quarterly conference calls. The Company instead will schedule conference calls in relation to relevant material corporate developments.

About PharmAthene, Inc.PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax™ - a second generation recombinant protective antigen (rPA) anthrax vaccine and a third gen
    '/>"/>

  • SOURCE PharmAthene, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
    2. PharmAthene Strengthens Scientific Leadership and Program Management for Future Growth
    3. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
    4. PharmAthene Reports Third Quarter 2010 Financial and Operational Results
    5. PharmAthene Receives Four Therapeutic Discovery Project Grants Totaling Approximately $850,000
    6. PharmAthene Announces Pricing of $15 Million Public Offering
    7. PharmAthene Announces Proposed Common Stock Offering
    8. PharmAthene Announces $3.9 Million Registered Direct Offering
    9. PharmAthene CEO To Participate on Biosecurity Panel at the 2010 BIO International Conference
    10. PharmAthene Appoints Mitchel Sayare, Ph.D. to the Companys Board of Directors
    11. PharmAthene Reports Year-End 2009 Financial and Operational Results and Provides Update On Ongoing Litigation With SIGA Technologies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/1/2015)... RARITAN, N.J. , June 1, ... announced data from the Phase 3 multicenter study ... survival (PFS) with trabectedin (YONDELIS ® ) compared ... or leiomyosarcoma (LMS) previously treated with an anthracycline ... is the largest randomized Phase 3 study ever ...
    (Date:6/1/2015)... 2015 About Bio-alcohols Bio-alcohols ... or cellulose. Bio-alcohols are primarily used in the transportation ... replacement for gasoline in cars. Technavio,s analysts forecast the ... 9 percent over the period 2014-2019. ... be segmented into five: transportation, infrastructure, medical, and others. ...
    (Date:6/1/2015)... , June 1, 2015  Novartis is highlighting ... of CTL019, an investigational chimeric antigen receptor (CAR) ... the treatment of specific types of hard-to-treat non-Hodgkin ... the University of Pennsylvania,s Perelman School of Medicine ... diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma ...
    (Date:6/1/2015)... 2015  The Val Skinner Foundation is partnering with ... for high school students focused on cancer genetics. Skinner ... LIFE Event (LPGA Pros in the Fight to Eradicate ... West Caldwell, N.J. ... more than $500,000 on Monday, bringing the foundation,s 16-year ...
    Breaking Biology Technology:Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 4Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 5Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 6Global Bio-alcohols Market 2015-2019 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6Val Skinner Foundation Announces Partnership With Discovery Education 2
    ... FULLERTON, Calif., Dec. 28 Beckman Coulter,Inc. ... manufacturer, and marketer of,products that simplify, automate, ... Scott Garrett, Beckman Coulter,s president and chief,executive ... Conference on,Tuesday, January 8, 2008, at 6:00 ...
    ... Hold Loramyc(R) ... Zensana(TM) Reformulation Complete, Resubmission ... Par,Pharmaceutical Companies, Inc. (NYSE: PRX ) ... its three, in-licensed, proprietary pipeline,products: pafuramidine, Loramyc(R) (miconazole ...
    ... Systems, Inc., (OTC Bulletin Board: IMDS) a pioneer ... Tim Hansen will be,retiring as Chief Executive Officer ... http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO ), Tim Hansen was ... of,the Company by the Board of Directors in ...
    Cached Biology Technology:Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products 2Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products 3Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products 4Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products 5Imaging Diagnostic Systems CEO Announces Retirement 2Imaging Diagnostic Systems CEO Announces Retirement 3
    (Date:6/1/2015)... June 1, 2015 According ... Biometrics Market by Application (Government, Military & Defense, ... Immigration, and Security), Technology (Face Recognition, Fingerprint Recognition, ... Vein Recognition, and Others), Function (Contact and Non-Contact) ... Europe , APAC, Row) - ...
    (Date:5/27/2015)... CLEVELAND , May 27, 2015 /PRNewswire/ ... in medication safety systems and image documentation ... provider of comprehensive, technologically-advanced automation solutions, is ... art integration. The Codonics® Safe Label System® ... used in conjunction with the Omnicell Anesthesia ...
    (Date:5/22/2015)... May 22, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... will be ending its promotional pricing and making the Wocket ... Laurence Savin , Head of Marketing said, "We,ve extended ... until the end of May. To get your wocket at ... we open the store on June 1, you,ll receive a ...
    Breaking Biology News(10 mins):Next Generation Biometrics Market Worth $24,448.84 Million by 2020 2Next Generation Biometrics Market Worth $24,448.84 Million by 2020 3Next Generation Biometrics Market Worth $24,448.84 Million by 2020 4Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3
    ... Rockville, Md., August 26, 2010 Recent incidents ... pet food with the industrial chemical melamine revealed the ... and global food industry for determining protein content in ... methods is the subject of a new paper published ...
    ... next generation of neutron research at Indiana University Bloomington ... Institute for Standards and Technology. A recently awarded NIST ... five years to support cooperative research activities between the ... NIST,s National Center for Neutron Research, located in Gaithersburg, ...
    ... million grant from the National Institutes of Health ... translate new scientific findings and technological developments into ... designates Nationwide Children,s Hospital as a Paul D. ... three national award recipients in 2010. ...
    Cached Biology News:New paper examines approaches to measuring protein in foods in context of deadly adulterations 2New paper examines approaches to measuring protein in foods in context of deadly adulterations 3New paper examines approaches to measuring protein in foods in context of deadly adulterations 4IU physics facility awarded $5 million for cooperative neutron research 2$7 million grant designates Nationwide Children's as Wellstone Center 2
    Schneider's Drosophila - Insect medium...
    ... more than doubles the benefits of high ... analysis cycles of the standard binary system ... tandem mode. Difficult separations are dramatically improved ... heartcut configurations, on-line sample preparation is fully ...
    ... the gene supplied by a customer. Mutated DNA ... choice to obtain a library of the mutated ... a desired value within 1-20 mutations per kb. ... be restricted to a desired region of a ...
    ... Highly-purified, endotoxin-free plasmid DNA preparations are ... in quantities from 1mg to multi-gram ... to customer needs, and glycerol stocks ... , Transformation, clonal selection (Clonal selection ...
    Biology Products: